What is XDC conjugate?

XDC represent a broad category of bioconjugates, it is a general term for various drug conjugates, consisting of a tumor targeting moiety (X), a payload drug (D) and a sophisticatedly designed chemical linker.

In the rapidly advancing field of precision oncology, the traditional "one-size-fits-all" approach to chemotherapy is being superseded. We have entered the era of X-Drug Conjugates (XDC)—a modular "Everything-Drug Conjugate" framework that redefines the delivery of cytotoxic payloads to malignant cells.

As medicinal chemists assert, the primary challenge of XDC lies not just in identifying the optimal drug, but in engineering the "molecular bridge" that transports it. This is the "Stability-Release Paradox"—a critical equilibrium that dictates clinical success or failure.

An ideal XDC remains stable in blood circulation, reaches the therapeutic target accurately, and eventually releases the cytotoxic payloads in the vicinity of the targets. Every part will affect the final efficacy and safety of XDC, therefore, the selection of targeting molecule, cytotoxic drug, linker, as well as conjugation methods are all needs to be taken into account in developing an XDC.

Key Aspects of XDC Conjugation:

Targeting Moieties (X): The repertoire has expanded to include peptides (PDCs), small molecules (SMDCs), and aptamers.

Bispecific XDCs (Bi-XDCs): This dual-targeting strategy utilizes bivalent recognition of two distinct antigens (e.g., PSMA and FRα). This achieves synergistic binding and addresses the recalcitrant issues of tumor antigen escape and acquired resistance.

Therapeutic Payloads (D): The field is embracing topoisomerase I inhibitors (Dxd, SN-38), PROTACs, and even STING agonists.

Linker Architectures: The "soul" of the XDC. Linkers must maintain exceptional systemic stability to prevent off-target toxicity while ensuring precise triggered release upon reaching the target cell. Linker instability is a primary driver of clinical failure, leading to premature payload shedding and severe systemic side effects

Resolving the Stability-Release Paradox.

1. The Gold Standard: Val-Cit

   The Valine-Citrulline (Val-Cit) dipeptide remains the industry gold standard for enzymatically triggered release. Val-Cit linkers provide:

   • Superior Plasma Stability: Minimizing payload "leakage" during systemic circulation.
   • Rapid Intracellular Kinetics: Ensuring efficient cleavage by Cathepsin B once the conjugate is internalized via endocytosis.

   Figure 1: Val-Cit (BP-24335)

   

2. 100% Potency Restoration: Self-Immolative PAB Technology

   Residual linker fragments attached to the payload post-cleavage can significantly attenuate drug efficacy. Scientists resolve this through Self-Immolative Spacers. Upon enzymatic cleavage of the Val-Cit bond, the p-aminobenzyl alcohol (PAB) moiety undergoes a spontaneous 1,6-elimination reaction and decarboxylation, "ejecting" the payload in its native, unmodified form to ensure 100% biological activity restoration.

   

   Figure 2: Val-Cit-PAB-OH (BP-23218)

   

3. The Future of Delivery: PDCs and Bi-XDCs

   As we look toward 2026, the industry focus has shifted to "High Penetration" and "Precision Targeting."

   • Peptide-Drug Conjugates (PDCs): Compared to 150 kDa antibodies, PDCs have a molecular weight of only ≈2–5 kDa, granting them superior solid tumor penetration. BroadPharm’s high-purity PEG linkers are vital here, enhancing the solubility and pharmacokinetics of hydrophobic constructs.
   • Dual-Targeting Strategies: Bi-XDCs leverage dual-antigen coverage to enhance affinity and drastically reduce the risk of resistance caused by single-antigen loss.

   
   

4. BroadPharm Technical Advantage

   Industry Challenge	Solution	Clinical Impact
   Off-target Toxicity	Optimized Ultra-stable Val-Cit sequences	Significantly reduces systemic side effects (e.g., neutropenia).
   Attenuated Potency	Self-Immolative PAB Technology	Fully restores pharmacological potency and efficacy.
   Production Scalability	BroadPharm provides mg to kg Scalable Synthesis	Facilitates seamless transition from R&D to Phase I trials.
   Complex Payload Matching	8,000+ Modular Linker Library	Compatible with ADCs, PDCs, and Radioconjugates (RDCs).




5. BroadPharm Tailored Solutions for Bi-XDCs and PDCs

   5.1 Peptide-Drug Conjugate (PDC) Optimization

   PDCs often suffer from rapid renal clearance and poor solubility.

   • Monodisperse PEG Derivatives: Provide precise molecular weight control with zero polydispersity, significantly enhancing water solubility and extending in vivo half-life.
   • Enzymatically Cleavable Peptide Linkers: Specifically Val-Cit-PAB for efficient triggered release following rapid cellular uptake.

   5.2 Bispecific XDC (Bi-XDC) Architecture

   Bi-XDCs require the precise conjugation of two targeting ligands and a payload on a single molecule, necessitating Branched and Multifunctional linkers.

   • Branched PEG Linkers: Allow for the attachment of multiple ligands or payloads (High DAR) on a single scaffold to overcome antigen heterogeneity.
   • Orthogonal Functional Linkers: Support simultaneous orthogonal reactions (e.g., Copper-free Click Chemistry and Thiol addition) to ensure precise positioning of dual targeting moieties.



6. BroadPharm Empowering Next-Generation "Super-Chemotherapy"

   The evolution from ADC to the broader XDC landscape requires more than just potent payloads; it demands sophisticated, high-performance "connectivity" solutions. BroadPharm provides an integrated platform—from bespoke chemical design to large-scale cGMP-ready production—bridging the gap between innovative research and life-saving clinical treatments.

Whether you are targeting a novel biomarker or optimizing a complex Bi-XDC, BroadPharm team offers expert linker conjugation strategies and detailed structural recommendations to accelerate your drug development timeline.

References

Chen B, Kang W, et al. Antibody–drug conjugates in cancer therapy: current landscape, challenges, and future directions. Mol Cancer. 2024;23(1):161. doi:10.1186/s12943-024-01939-w

Coherent Biopharma. Updated results from a phase I/II study of CBP-1018, a bi-ligand drug conjugate (Bi-XDC) as late-line therapy for patients with metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol. 2025;43(5_suppl):Abstract 161. doi:10.1200/JCO.2025.43.5_suppl.161